

Zelira Therapeutics Ltd.

08:10 11 Jul 2019

Zelda Therapeutics responds to ASX query on price and volume increases

Zelda Therapeutics Ltd (ASX:ZLD) was queried by the ASX yesterday relating to the price of its securities, which went from a low of 4.6 cents at the close of trading on July 8 to a high of 6.7 cents yesterday, July 10.

The ASX also noted the increase in the volume of Zelda's securities traded during the same period.

Zelda responded to the query explaining that it was not aware of any information that had not been released to market which, if known by some in the market, could explain the recent trading in its securities.

The company also reconfirmed that it recently received formal approval for its Phase I Opioid Reduction Trial from the St Vincent's Hospital Ethics and Governance Committees.

READ: Zelda Therapeutics to begin opioid reduction trial with approval granted

The Phase I trial will evaluate the safety and tolerability of whole plant extract following single and repeated doses in nine patients with chronic non-cancer pain on long-term opioid analgesia.

Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the trial.

The Phase I trial has commenced with preliminary results expected by late Q3 2019 and final results in Q4 2019, which is similar to the timeframe the company expects to report on its ongoing Phase II Insomnia trial.

Zelda's CEO has also continued to make presentations in relation to the company's business and its objectives, which have been well attended by investors.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that

Price: 0.0525

Market Cap: \$39.84 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.091 0.033

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.

action@proactiveinvestors.com

contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd. named herein, including the promotion by the Company of Zelira Therapeutics Ltd. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).